Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Reduction of Myocardial Infarct Size by the Calcium Antagonist FR 7534

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study was conducted to determine the effect of FR 7534, a light-stable derivative of nifedipine on hemodynamics, coronary collateral blood flow and myocardial infarct size in the anesthetized dog. Myocardial infarction was produced by a 2-hour occlusion and reperfusion of the distal third of the left anterior descending coronary artery in control dogs, FR 7534-treated dogs and FR 7534-treated dogs with a constant aortic blood pressure. FR 7534 alone produced significant decreases in heart rate and mean aortic blood pressure, however, no change in collateral blood flow of central ischemic zones was observed. On the other hand, when aortic blood pressure was held constant, FR 7534 produced a significant increase in coronary collateral blood flow. With or without a constant aortic perfusion pressure, FR 7534 significantly reduced infarct size as compared to control experiments (33.5 to 4.3 and 7.5% of the area at risk infarcted, respectively). The present results demonstrate the efficacy of a new calcium antagonist, FR 7534, to protect ischemic myocardium with or without a change in oxygen supply via the coronary collateral circulation.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1981
          1981
          07 November 2008
          : 68
          : 3
          : 146-160
          Affiliations
          Departments of Medicine, Division of Cardiology and Pharmacology and Toxicology, The Medical College of Wisconsin, Milwaukee, Wisc., USA
          Article
          173276 Cardiology 1981;68:146–160
          10.1159/000173276
          7317884
          © 1981 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 15
          Categories
          Original Paper

          Comments

          Comment on this article